177 related articles for article (PubMed ID: 10623800)
1. The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire.
Hernández J; Lee PP; Davis MM; Sherman LA
J Immunol; 2000 Jan; 164(2):596-602. PubMed ID: 10623800
[TBL] [Abstract][Full Text] [Related]
2. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
3. The use of transgenic mice to generate high affinity p53 specific cytolytic T cells.
Yu Z; Liu X; McCarty TM; Diamond DJ; Ellenhorn JD
J Surg Res; 1997 May; 69(2):337-43. PubMed ID: 9224403
[TBL] [Abstract][Full Text] [Related]
4. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
5. High avidity antigen-specific CTL identified by CD8-independent tetramer staining.
Choi EM; Chen JL; Wooldridge L; Salio M; Lissina A; Lissin N; Hermans IF; Silk JD; Mirza F; Palmowski MJ; Dunbar PR; Jakobsen BK; Sewell AK; Cerundolo V
J Immunol; 2003 Nov; 171(10):5116-23. PubMed ID: 14607910
[TBL] [Abstract][Full Text] [Related]
6. CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen.
Hernández J; Ko A; Sherman LA
J Immunol; 2001 Mar; 166(6):3908-14. PubMed ID: 11238635
[TBL] [Abstract][Full Text] [Related]
7. Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.
Theobald M; Biggs J; Hernández J; Lustgarten J; Labadie C; Sherman LA
J Exp Med; 1997 Mar; 185(5):833-41. PubMed ID: 9120389
[TBL] [Abstract][Full Text] [Related]
8. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity.
Colombetti S; Fagerberg T; Baumgärtner P; Chapatte L; Speiser DE; Rufer N; Michielin O; Lévy F
J Immunol; 2006 Jun; 176(11):6560-7. PubMed ID: 16709813
[TBL] [Abstract][Full Text] [Related]
9. Diversity and dominance among TCR recognizing HLA-A2.1+ influenza matrix peptide in human MHC class I transgenic mice.
Man S; Ridge JP; Engelhard VH
J Immunol; 1994 Nov; 153(10):4458-67. PubMed ID: 7963521
[TBL] [Abstract][Full Text] [Related]
10. Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
Lotz C; Mutallib SA; Oehlrich N; Liewer U; Ferreira EA; Moos M; Hundemer M; Schneider S; Strand S; Huber C; Goldschmidt H; Theobald M
J Immunol; 2005 Jul; 175(2):1301-9. PubMed ID: 16002735
[TBL] [Abstract][Full Text] [Related]
11. The ability of variant peptides to reverse the nonresponsiveness of T lymphocytes to the wild-type sequence p53(264-272) epitope.
Hoffmann TK; Loftus DJ; Nakano K; Maeurer MJ; Chikamatsu K; Appella E; Whiteside TL; DeLeo AB
J Immunol; 2002 Feb; 168(3):1338-47. PubMed ID: 11801674
[TBL] [Abstract][Full Text] [Related]
12. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer.
Ichiki Y; Takenoyama M; Mizukami M; So T; Sugaya M; Yasuda M; So T; Hanagiri T; Sugio K; Yasumoto K
J Immunol; 2004 Apr; 172(8):4844-50. PubMed ID: 15067062
[TBL] [Abstract][Full Text] [Related]
14. Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant.
McArdle SE; Rees RC; Mulcahy KA; Saba J; McIntyre CA; Murray AK
Cancer Immunol Immunother; 2000 Oct; 49(8):417-25. PubMed ID: 11043848
[TBL] [Abstract][Full Text] [Related]
15. Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity.
Petersen TR; Buus S; Brunak S; Nissen MH; Sherman LA; Claesson MH
Scand J Immunol; 2001 Apr; 53(4):357-64. PubMed ID: 11285115
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
[TBL] [Abstract][Full Text] [Related]
17. H-2-restricted cytolytic T lymphocytes specific for HLA display T cell receptors of limited diversity.
Casanova JL; Cerottini JC; Matthes M; Necker A; Gournier H; Barra C; Widmann C; MacDonald HR; Lemonnier F; Malissen B; Maryanski JL
J Exp Med; 1992 Aug; 176(2):439-47. PubMed ID: 1380061
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.
Barfoed AM; Petersen TR; Kirkin AF; Thor Straten P; Claesson MH; Zeuthen J
Scand J Immunol; 2000 Feb; 51(2):128-33. PubMed ID: 10652158
[TBL] [Abstract][Full Text] [Related]
19. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen.
Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J
Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571
[TBL] [Abstract][Full Text] [Related]
20. A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells.
Epel M; Ellenhorn JD; Diamond DJ; Reiter Y
Cancer Immunol Immunother; 2002 Nov; 51(10):565-73. PubMed ID: 12384808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
